Prostate Cancer

Dr. Howard Sandler from Cedars-Sinai Medical Center discusses the TAK-700 in Localized Prostate Cancer Clinical Trials

The federal agency that determines Medicare reimbursements this week proposed to fully cover the cost of Provenge

Robert Dreicer, MD, from the Taussig Cancer Institute, Discusses How New Treatments Have Improved Survival

In an interview at the 2011 IPCC Meeting in New York, Leonard G. Gomella, MD, from Jefferson Kimmel Cancer Center, discusses prostate cancer screening procedures.

Robert Dreicer, MD, from the Taussig Cancer Institute, discusses the various treatments that prostate cancer patients may receive in combination.

Howard M. Sandler, MD, MS, from Cedars-Sinai Medical Center, discusses candidates for liase inhibitor clinical trials.

Howard M. Sandler, MD, MS, from Cedars-Sinai Medical Center, compares the efficacy of the mechanism of action for traditional LHRH agonists to newer androgen deprivation therapies

Daniel P. Petrylak, MD, from Columbia University Medical Center Explains the Difficulties Facing During Prostate Cancer Clinical Trials

According to a retrospective review of a SEER-Medicare database presented at the ASCO Genitourinary Cancers Symposium

Performing robotic-assisted laparoscopic radical prostatectomy (RALP) surgeries at an expert level is not as easy as has been previously assumed

According to primary results of a phase III randomized, placebocontrolled trial reported at the 2011 ASCO Genitourinary Cancers Symposium

A recent clinical study reviewed the surprising results of a new prostate cancer test.

Dutasteride, a drug commonly used to treat benign prostatic hyperplasia, may also be useful as part of a "watchful waiting" strategy

cabozantinib (XL184) - a novel wide-spectrum tyrosine kinase inhibitor (TKI) - achieved dramatic results in patients with castration-resistant prostate cancer

Though taking multivitamins has been linked to potential health benefits, a new study has found that an excessive consumption of multivitamins may not be beneficial.

Researchers are calling for prostate cancer survivors to incorporate physical activity into their daily routine.

Robert S. Alter, M.D. Co-chief, Urologic Oncology, John Theurer Cancer Center, on prostate cancer research that was presented at the 2011 ASCO Genitourinary meeting.

The FDA has released briefing documents noting that the 5-alpha reductase inhibitor increases the risk of high-risk prostate cancer.

According to the British Journal of Cancer, a new study by London's Institute of Cancer Research finds that finger length might be an indicator of prostate cancer risk.